News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • BOJ lifted its policy rate to a 31-year high.
  • Japanese yen weakened despite the BOJ rate increase.
  • US dollar remained supported by expectations of further Fed tightening.
  • Asian currencies diverged across the region.
  • Regional FX volatility increased in response to shifting yield differentials.
  • Traders reassessed the likely path for global monetary policy.

Latest Articles

Synthomer lifts 2026 guidance after H1 revenue climbs 6.7%

Synthomer lifts 2026 guidance after H1 revenue climbs 6.7%

Synthomer reported H1 revenue of £954.30 million, a year-on-year increase of 6.7%, and upgraded its full-year 2026 outlook to slightly ahead of market expectations. Adjusted earnings per share turned positive at £0.22 and adjusted pretax profit exceeded estimates, although the group recorded an overall pretax loss and negative free cash flow for th…

Taiwan market ends flat as select stocks swing sharply at close

Taiwan market ends flat as select stocks swing sharply at close

Taiwan's main index finished the session unchanged, even as a handful of listed companies swung markedly in late trade. Market breadth favored advancers, and energy and precious metals contracts advanced. Currency moves were small, with the TWD little changed against the US dollar and the yuan showing a marginal figure in the report.

Tokyo and Washington Ready to Act Again if Yen Weakens, Former BOJ Official Says

Tokyo and Washington Ready to Act Again if Yen Weakens, Former BOJ Official Says

A former Bank of Japan official directly involved in past market operations warned that Japan and the United States are prepared to repeat joint intervention if the yen resumes a fresh downtrend. He said the recent rare coordinated yen-buying operation successfully altered market perceptions, and that the U.S. backing gives Tokyo freedom to act aga…

Wage Talks Stall at Port Hedland as Unions Advance Weekend Strike Plan

Wage Talks Stall at Port Hedland as Unions Advance Weekend Strike Plan

Unions representing workers at BHP’s Port Hedland operations in Western Australia said on Aug 4 that they have not reached agreement on wages with the miner, and will proceed with a planned two-day strike at the world’s largest iron ore export hub on August 8-9. Both sides signalled further talks, with BHP due to put forward an updated proposal at …

Rio Tinto not expected to reopen Glencore merger talks as standstill lapses

Rio Tinto not expected to reopen Glencore merger talks as standstill lapses

A six-month standstill that barred Rio Tinto from approaching Glencore lapses this week, but sources close to Rio's leadership say the company is unlikely to renew merger discussions. CEO Simon Trott is focused on simplifying the business into three core divisions, selling assets to free up cash and expanding copper and trading activities rather th…

Sustainable Fund Launches Falter as Performance, Flows and Regulation Bite

Sustainable Fund Launches Falter as Performance, Flows and Regulation Bite

New launches of sustainable funds have slowed sharply in 2026, with Europe recording a near-record low of new products in the second quarter while dozens of funds closed. Weak returns, investor redemptions and intensified regulatory attention have prompted fund managers to retreat from or reshape sustainability-labelled offerings, with flows favour…

Death of Bologna Businessman Puts Human Face on Europe’s Migration Row

Death of Bologna Businessman Puts Human Face on Europe’s Migration Row

The death of 42-year-old Moroccan-born metalworker Abderrahim Fakir after being restrained by police in Bologna has intensified Italy’s migrant debate. While political leaders used the incident to advance competing narratives, interviews with family, lawyers and friends depict a man contending with business troubles, anxiety over his residency and …

IQM Quantum Computers Reports First Earnings as Public Company, Reporting First Half and Second Quarter 2026 Results, and Initiates FY 2026 Guidance Supported by Over EUR 102 million Order Backlog

IQM Quantum Computers Reports First Earnings as Public Company, Reporting First Half and Second Quarter 2026 Results, and Initiates FY 2026 Guidance Supported by Over EUR 102 million Order Backlog

IQM Quantum Computers Plc, a Finnish-based global leader in superconducting quantum computers, announced its first earnings as a public company for H1 and Q2 2026. The company reported EUR 8.9 million in revenues and an operating loss of EUR 60.5 million, supported by a substantial cash balance of EUR 309.4 million post listing. IQM expanded its ma…

Wix Reports Second Quarter 2026 Results

Wix Reports Second Quarter 2026 Results

Wix.com Ltd. announced robust second quarter 2026 financial results, with revenues increasing 15% year-over-year to $563 million, fueled by strong performance in its Base44 app-creation platform and continued growth in its core Wix business. The company launched Base44’s proprietary large language model (LLM) 'Base 1' to reduce AI operational costs…

Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Nurix Therapeutics has enrolled the first patient in its pivotal Phase 3 DAYBreak CLL-306 trial evaluating bexobrutideg, a novel BTK degrader, against standard non-covalent BTK inhibitor pirtobrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. The trial aims to demonstrate bexobrutideg’s superi…

WuXi AppTec Shares Jump After Strong H1 2026 Results and Raised Guidance

WuXi AppTec Shares Jump After Strong H1 2026 Results and Raised Guidance

WuXi AppTec's stock climbed sharply after the company reported first-half 2026 revenue of RMB 28.9 billion and net profit attributable to shareholders of RMB 11.08 billion, both well ahead of market expectations. Adjusted non-IFRS net profit rose markedly, the company raised full-year revenue guidance, and declared an interim cash dividend payable …

WuXi AppTec Shares Surge to Nearly Five-Year Peak After Strong H1 Results

WuXi AppTec Shares Surge to Nearly Five-Year Peak After Strong H1 Results

WuXi AppTec's H shares climbed more than 10% in Hong Kong to trade at their highest level since September 30, 2021, following first-half results that beat expectations. The Chinese contract research and manufacturing services firm reported a 33.7% rise in net profit attributable and a near 39% increase in revenue, driven by broad-based demand inclu…

India to Table Tax Bills to Attract Foreign Capital and Bolster Manufacturing

India to Table Tax Bills to Attract Foreign Capital and Bolster Manufacturing

The Indian government intends to seek parliamentary approval for a package of tax measures designed to draw foreign investment and reinforce domestic manufacturing capacity. Proposed legislation would formalize tax exemptions for foreign buyers of Indian government bonds, protect offshore funds from tax where management is India-based, and extend t…

Guggenheim Names Celldex Its Top Biotech Pick Ahead of Fall Phase III Data

Guggenheim Names Celldex Its Top Biotech Pick Ahead of Fall Phase III Data

Guggenheim Securities has designated Celldex Therapeutics as its leading biotechnology selection, highlighting the commercial promise of the company’s lead candidate, barzolvolimab, in the chronic urticaria market. Analysts kept a Buy rating and a $100 price target while pointing to approaching Phase III topline readouts and additional clinical upd…

Gotham City Research Accuses Sumitomo Pharma of Inflating FY2025 Revenue

Gotham City Research Accuses Sumitomo Pharma of Inflating FY2025 Revenue

Short seller Gotham City Research alleges Sumitomo Pharmaceutical misstated parts of its fiscal 2025 accounts by up to 165 billion yen, highlighting conflicting disclosures about a dividend from its Swiss subsidiary and claiming receivables were manipulated to boost profits. The report coincided with a 3.5%-4% drop in Sumitomo Pharma and Sumitomo C…